KENALOG-10

Clinical safety rating: caution

Comprehensive clinical and safety monograph for KENALOG-10 (KENALOG-10).

How it works

Triamcinolone acetonide is a synthetic corticosteroid with anti-inflammatory, immunosuppressive, and antiproliferative actions. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production (e.g., IL-1, IL-2, TNF-alpha). It also stabilizes lysosomal membranes and inhibits fibroblast proliferation.

What the body does with it

Metabolism	Primarily hepatic via CYP3A4. Triamcinolone acetonide is metabolized to inactive metabolites, mainly 6β-hydroxytriamcinolone acetonide. Less than 1% excreted unchanged in urine.
Excretion	Primarily hepatic metabolism (~80%) followed by renal excretion of inactive metabolites (glucuronide and sulfate conjugates). Unchanged triamcinolone acetonide accounts for <5% of urinary recovery. Biliary/fecal excretion is minor.
Half-life	Terminal elimination half-life is approximately 2–5 hours for triamcinolone acetonide. However, the duration of action is prolonged due to the crystalline suspension's slow dissolution from the injection site, resulting in a prolonged residence time and effects lasting weeks. The plasma half-life primarily reflects systemic clearance after absorption.
Protein binding	Approximately 68–79% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin (CBG).
Volume of Distribution	Apparent volume of distribution is approximately 0.2–0.5 L/kg. This low Vd reflects limited extravascular distribution and high protein binding.
Bioavailability	Intramuscular administration: 100% bioavailable (by design, as it is a depot formulation). Oral: Not applicable (not available). Intra-articular: Bioavailability is essentially 100% at the local site, but systemic absorption is limited; peak plasma concentrations are lower than after IM injection due to slow release.
Onset of Action	Intra-articular/soft tissue injection: Onset of anti-inflammatory effect occurs within 24–48 hours, though pain relief may begin within hours. Intramuscular administration: Onset is within 1–2 hours for systemic effects.
Duration of Action	Intra-articular injection: Duration of symptomatic relief typically lasts 1–2 weeks for small joints and up to 3–4 weeks for larger joints (e.g., knee). Intramuscular depot: Systemic glucocorticoid effects may persist for 2–3 weeks due to slow release. The duration is variable and depends on dose, injection site, and individual factors.

Classification & Brands

Dosing & administration

Intra-articular, intrabursal, or soft tissue injection: 10-40 mg (0.25-1 mL of 10 mg/mL) for large joints; 10 mg (0.25 mL) for small joints; repeat every 3-4 weeks if needed. Intralesional: 10-40 mg (0.25-1 mL) per lesion; maximum 1 mL per injection site; repeat every 1-2 weeks.

Dosage form	INJECTABLE
Renal impairment	No specific GFR-based dose adjustment required; use caution in severe renal impairment due to potential systemic effects.
Liver impairment	No specific Child-Pugh-based dose adjustment; use caution in severe hepatic impairment due to potential corticosteroid-related adverse effects.
Pediatric use	Intra-articular: 5-20 mg for large joints, 2.5-10 mg for small joints; intralesional: 2.5-10 mg per lesion; dose based on body surface area (BSA) and severity; not recommended for children under 12 unless directed by specialist.
Geriatric use	Initiate at lower end of dosing range (e.g., 10-20 mg intra-articular); monitor for increased susceptibility to corticosteroid side effects, including osteoporosis, hyperglycemia, and immunosuppression; avoid repeated injections in weight-bearing joints.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for KENALOG-10 (KENALOG-10).

Breastfeeding	Triamcinolone acetonide (KENALOG-10) is excreted in human milk in low amounts. M/P ratio not established. Potential for adrenal suppression in infant. Use with caution during breastfeeding, especially at high doses or prolonged therapy.
Teratogenic Risk	First trimester: increased risk of cleft palate (odds ratio 1.3-6.7). Second/third trimester: fetal growth restriction, adrenal suppression, hypothalamic-pituitary-adrenal axis suppression. Chronic use: low birth weight, preterm birth.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

No FDA boxed warning specific to KENALOG-10; however, corticosteroids in general have warnings for increased mortality in certain conditions (e.g., systemic fungal infections, cerebral malaria). Avoid live vaccines during therapy.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Systemic fungal infections","Hypersensitivity to triamcinolone or any component","Intrathecal administration (risk of arachnoiditis, neurological injury)","Live or live-attenuated vaccines (theoretical risk of disseminated infection)","Relative: Active tuberculosis, untreated bacterial/viral infections, recent vaccination"]

Clinical Precautions

Precautions

["Hypothalamic-pituitary-adrenal (HPA) axis suppression with prolonged use or high doses","Increased susceptibility to infections and masking of infection signs","Cushing's syndrome, osteoporosis, avascular necrosis, myopathy, peptic ulcer, pancreatitis","Ophthalmic effects: cataracts, glaucoma, central serous chorioretinopathy","Psychiatric disturbances (euphoria, depression, psychosis)","Fetal harm (Pregnancy Category C); use only if benefit outweighs risk"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

KENALOG-10

Clinical safety rating: caution

Comprehensive clinical and safety monograph for KENALOG-10 (KENALOG-10).

How it works

What the body does with it

Metabolism	Primarily hepatic via CYP3A4. Triamcinolone acetonide is metabolized to inactive metabolites, mainly 6β-hydroxytriamcinolone acetonide. Less than 1% excreted unchanged in urine.
Excretion	Primarily hepatic metabolism (~80%) followed by renal excretion of inactive metabolites (glucuronide and sulfate conjugates). Unchanged triamcinolone acetonide accounts for <5% of urinary recovery. Biliary/fecal excretion is minor.
Half-life	Terminal elimination half-life is approximately 2–5 hours for triamcinolone acetonide. However, the duration of action is prolonged due to the crystalline suspension's slow dissolution from the injection site, resulting in a prolonged residence time and effects lasting weeks. The plasma half-life primarily reflects systemic clearance after absorption.
Protein binding	Approximately 68–79% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin (CBG).
Volume of Distribution	Apparent volume of distribution is approximately 0.2–0.5 L/kg. This low Vd reflects limited extravascular distribution and high protein binding.
Bioavailability	Intramuscular administration: 100% bioavailable (by design, as it is a depot formulation). Oral: Not applicable (not available). Intra-articular: Bioavailability is essentially 100% at the local site, but systemic absorption is limited; peak plasma concentrations are lower than after IM injection due to slow release.
Onset of Action	Intra-articular/soft tissue injection: Onset of anti-inflammatory effect occurs within 24–48 hours, though pain relief may begin within hours. Intramuscular administration: Onset is within 1–2 hours for systemic effects.
Duration of Action	Intra-articular injection: Duration of symptomatic relief typically lasts 1–2 weeks for small joints and up to 3–4 weeks for larger joints (e.g., knee). Intramuscular depot: Systemic glucocorticoid effects may persist for 2–3 weeks due to slow release. The duration is variable and depends on dose, injection site, and individual factors.

Classification & Brands

Dosing & administration

Dosage form	INJECTABLE
Renal impairment	No specific GFR-based dose adjustment required; use caution in severe renal impairment due to potential systemic effects.
Liver impairment	No specific Child-Pugh-based dose adjustment; use caution in severe hepatic impairment due to potential corticosteroid-related adverse effects.
Pediatric use	Intra-articular: 5-20 mg for large joints, 2.5-10 mg for small joints; intralesional: 2.5-10 mg per lesion; dose based on body surface area (BSA) and severity; not recommended for children under 12 unless directed by specialist.
Geriatric use	Initiate at lower end of dosing range (e.g., 10-20 mg intra-articular); monitor for increased susceptibility to corticosteroid side effects, including osteoporosis, hyperglycemia, and immunosuppression; avoid repeated injections in weight-bearing joints.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for KENALOG-10 (KENALOG-10).

Breastfeeding	Triamcinolone acetonide (KENALOG-10) is excreted in human milk in low amounts. M/P ratio not established. Potential for adrenal suppression in infant. Use with caution during breastfeeding, especially at high doses or prolonged therapy.
Teratogenic Risk	First trimester: increased risk of cleft palate (odds ratio 1.3-6.7). Second/third trimester: fetal growth restriction, adrenal suppression, hypothalamic-pituitary-adrenal axis suppression. Chronic use: low birth weight, preterm birth.
Fetal Monitoring